Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491175 | 0.88 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2GAAPKMGRM1 | |
| SCHEMBL4488936 | 0.83 | MAPT (0.50) | ALDH1A1SMN1; SMN2GAAPKMRAB9A | |
| SCHEMBL4482553 | 0.80 | CUL4A (0.52) | ALDH1A1SMN1; SMN2RAB9ATSHRMAPT | |
| SCHEMBL4495523 | 0.80 | TNKS (0.39) | ALDH1A1SMN1; SMN2GAAPKMRAB9A | |
| SCHEMBL4485871 | 0.80 | CCR2 (0.38) | ALDH1A1SMN1; SMN2GAAMAPTRXFP1 | |
| SCHEMBL4499753 | 0.80 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2GAARAB9ATSHR | |
| SCHEMBL4500067 | 0.80 | TNKS (0.40) | ALDH1A1SMN1; SMN2GAAPKMRAB9A | |
| SCHEMBL4497665 | 0.78 | MEN1 (0.55) | ALDH1A1SMN1; SMN2RAB9ATSHRMAPT | |
| SCHEMBL4499382 | 0.78 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GAAMAPTKMT2A | |
| SCHEMBL4499607 | 0.77 | KDM4E (0.44) | ALDH1A1PKMHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668009-A1 | HCV INHIBITORS AND METHODS OF USING THEM | Rigel Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | claimed |
| WO-2005030774-A1 | HCV INHIBITORS AND METHODS OF USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569580-B2 | Tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358259-B2 | Tetrazoloquinoline, triazoloquinoline, and oxazoloquinoline compounds, e.g., 9-chloro-N-isopropoxytetrazolo[1,5-a]quinoline-4-carboxamide | RIGEL PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050090521-A1 | HCV inhibitors and methods of using them | RIGEL PHARMACEUTICALS, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149520-A1 | HCV Inhibitors And Methods Of Using Them | HAVCR2, GLS2, EIF2AK2 | ALDH1A1 874/4885SMN1; SMN2 4478/4885GAA 122/4885 |
| US-20050090521-A1 | HCV inhibitors and methods of using them | HAVCR2, GLS2, EIF2AK2 | ALDH1A1 874/4885SMN1; SMN2 4478/4885GAA 122/4885 |
| US-20050282850-A1 | Heterotricylic compounds for use as HCV inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 2575/4885SMN1; SMN2 4606/4885GAA 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.